Abstract
Glucagon-like peptide 2 (GLP-2) appears to regulate growth of the small bowel epithelium. The importance of dose, vehicle, and route of administration for GLP-2 bioactivity was examined in vivo. Mouse small bowel weight increased following subcutaneous injection of GLP-2, 0.25 to 5.0 μg twice daily, with an increment in jejunal crypt plus villus height detected with only 250 ng GLP-2 twice daily for 14 days (1.35-fold greater than control, P <0.05). Small bowel weight was increased by 6 days of GLP-2 administration (1.4-fold greater than control, P <0.05) and further increased after up to 14 days of GLP-2 treatment (P <0.001, GLP-2 vs. control). GLP-2 increased small bowel weight in either 12% gelatin or phosphate-buffered saline (PBS) formulations (P <0.01 vs. P <0.05, gelatin vs. PBS, respectively), and GLP-2 was intestinotrophic following either intramuscular, intraperitoneal, or subcutaneous administration (P <0.05 for im and ip, P <0.001 for sc, GLP-2 vs. control). GLP-2 also induced bowel growth when administered daily or every other day. These results define important biological parameters for the activity of GLP-2 in vivo.
| Original language | English (US) |
|---|---|
| Journal | American Journal of Physiology - Gastrointestinal and Liver Physiology |
| Volume | 272 |
| Issue number | 3 35-3 |
| State | Published - Mar 1997 |
| Externally published | Yes |
Fingerprint
Keywords
- glucagon-like peptides
- growth factor
- intestine
- mouse
- small bowel
ASJC Scopus subject areas
- Gastroenterology
- Physiology
- Physiology (medical)
Cite this
Biological determinants of intestinotrophic properties of GLP-2 in vivo. / Tsai, Anne; Hill, Mary; Drucker, Daniel J.
In: American Journal of Physiology - Gastrointestinal and Liver Physiology, Vol. 272, No. 3 35-3, 03.1997.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Biological determinants of intestinotrophic properties of GLP-2 in vivo
AU - Tsai, Anne
AU - Hill, Mary
AU - Drucker, Daniel J.
PY - 1997/3
Y1 - 1997/3
N2 - Glucagon-like peptide 2 (GLP-2) appears to regulate growth of the small bowel epithelium. The importance of dose, vehicle, and route of administration for GLP-2 bioactivity was examined in vivo. Mouse small bowel weight increased following subcutaneous injection of GLP-2, 0.25 to 5.0 μg twice daily, with an increment in jejunal crypt plus villus height detected with only 250 ng GLP-2 twice daily for 14 days (1.35-fold greater than control, P <0.05). Small bowel weight was increased by 6 days of GLP-2 administration (1.4-fold greater than control, P <0.05) and further increased after up to 14 days of GLP-2 treatment (P <0.001, GLP-2 vs. control). GLP-2 increased small bowel weight in either 12% gelatin or phosphate-buffered saline (PBS) formulations (P <0.01 vs. P <0.05, gelatin vs. PBS, respectively), and GLP-2 was intestinotrophic following either intramuscular, intraperitoneal, or subcutaneous administration (P <0.05 for im and ip, P <0.001 for sc, GLP-2 vs. control). GLP-2 also induced bowel growth when administered daily or every other day. These results define important biological parameters for the activity of GLP-2 in vivo.
AB - Glucagon-like peptide 2 (GLP-2) appears to regulate growth of the small bowel epithelium. The importance of dose, vehicle, and route of administration for GLP-2 bioactivity was examined in vivo. Mouse small bowel weight increased following subcutaneous injection of GLP-2, 0.25 to 5.0 μg twice daily, with an increment in jejunal crypt plus villus height detected with only 250 ng GLP-2 twice daily for 14 days (1.35-fold greater than control, P <0.05). Small bowel weight was increased by 6 days of GLP-2 administration (1.4-fold greater than control, P <0.05) and further increased after up to 14 days of GLP-2 treatment (P <0.001, GLP-2 vs. control). GLP-2 increased small bowel weight in either 12% gelatin or phosphate-buffered saline (PBS) formulations (P <0.01 vs. P <0.05, gelatin vs. PBS, respectively), and GLP-2 was intestinotrophic following either intramuscular, intraperitoneal, or subcutaneous administration (P <0.05 for im and ip, P <0.001 for sc, GLP-2 vs. control). GLP-2 also induced bowel growth when administered daily or every other day. These results define important biological parameters for the activity of GLP-2 in vivo.
KW - glucagon-like peptides
KW - growth factor
KW - intestine
KW - mouse
KW - small bowel
UR - http://www.scopus.com/inward/record.url?scp=0030977884&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0030977884&partnerID=8YFLogxK
M3 - Article
VL - 272
JO - American Journal of Physiology - Renal Fluid and Electrolyte Physiology
JF - American Journal of Physiology - Renal Fluid and Electrolyte Physiology
SN - 1931-857X
IS - 3 35-3
ER -